INTRODUCCIÓN: REVISIÓN CRITICA DEL PROBLEMA

CAPÍTULO VIII
162. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M,
Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H. Novel splice variants of
the receptor for advanced glycation end-products expressed in human vascular
endothelial cells and pericytes, and their putative roles in diabetes-induced vascular
injury. Biochem J. 2003 Mar 15;370(Pt 3):1097-109.
163. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008
May;22(5):1572-80.
164. Santilli F, Vazzana N, Bucciarelli LG, Davì G. Soluble forms of RAGE in human diseases:
clinical and therapeutical implications. Curr Med Chem. 2009;16(8):940-52.
165. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, Grant PJ, Schmidt AM. Raucci
A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi
ME. A soluble form of the receptor for advanced glycation endproducts (RAGE) is
produced by proteolytic cleavage of the membrane-bound form by the sheddase a
disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008 Oct;22(10):3716-27.
166. Sárkány Z, Ikonen TP, Ferreira-da-Silva F, Saraiva MJ, Svergun D, Damas AM. Solution
structure of the soluble receptor for advanced glycation end products (sRAGE). J Biol
Chem. 2011 Oct 28;286(43):37525-34. Epub 2011 Aug 23.
167. Kalea AZ, Schmidt AM, Hudson BI. Alternative splicing of RAGE: roles in biology and
disease. Front Biosci. 2011 Jun 1;17:2756-70.
168. Yang SJ, Kim S, Hwang SY, Kim TN, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH,
Choi DS, Choi KM. Association between sRAGE, esRAGE levels and vascular
inflammation: Analysis with (18)F-fluorodeoxyglucose positron emission tomography.
Atherosclerosis. 2011 Nov 16.
169. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM.
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced
glycation endproducts. Nat Med. 1998 Sep;4(9):1025-31.
170. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, Jenkins DG, Stein G, Schmidt AM,
Yan SF. RAGE modulates vascular inflammation and atherosclerosis in a murine model
of type 2 diabetes. Atherosclerosis. 2006 Mar;185(1):70-7.
171. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T,
Lee DC, Kashyap Y, Stern DM, Schmidt AM. RAGE blockade stabilizes established
atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002 Nov
26;106(22):2827-35.
172. Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M. Soluble
receptor for advanced glycation end products: a new biomarker in diagnosis and
prognosis of chronic inflammatory diseases. Rheumatology (Oxford). 2009
Oct;48(10):1190-6. Review.
173. Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, Kang SW, Choi KH, Kim HJ, Yoo TH.
Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and
proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis
in patients with peritoneal dialysis. Atherosclerosis. 2011 Aug 5.
174. Kalousová M, Hodková M, Kazderová M, Fialová J, Tesar V, Dusilová-Sulková S, Zima T.
Soluble receptor for advanced glycation end products in patients with decreased renal
function. Am J Kidney Dis. 2006 Mar;47(3):406-11.
175. Koyama Y, Takeishi Y, Niizeki T, Suzuki S, Kitahara T, Sasaki T, Kubota I. Soluble Receptor
for advanced glycation end products (RAGE) is a prognostic factor for heart failure. J
Card Fail. 2008 Mar;14(2):133-9.
176. Yamagishi S, Matsui T, Nakamura K.Kinetics, role and therapeutic implications of
endogenous soluble form of receptor for advanced glycation end products (sRAGE) in
diabetes. Curr Drug Targets. 2007 Oct;8(10):1138-43.
177. Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation endproducts
and their receptor in inflammation and diabetes complications. Nat Clin Pract
Endocrinol Metab. 2008 May;4(5):285-93. Review.
234